GlassScriptPhysician profile
Eduardo Candanosa
NPI 1144512484
$4,820.23
in general payments reported to CMS, 2019-2025
33 companies · $813 in 2025
The $813 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $300 · 2021: $711 · 2022: $772 · 2023: $1,176 · 2024: $924 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,913.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,025.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $696.69 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $591.06 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $299.48 | 2023-2025 | |
| Amgen INC. | $215.16 | 2023-2025 | Otezla, Repatha, Krystexxa |
| Canon Medical Systems USA, INC. | $200.64 | 2025 | Interventional Angiography System |
| Astrazeneca Pharmaceuticals LP | $194.04 | 2021-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.53 | 2020-2024 | Jardiance |
| Abbott Laboratories | $148.75 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $137.64 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $132.51 | 2022-2025 | Austedo, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $112.97 | 2020-2023 | Xarelto |
| Viiv Healthcare Company | $99.77 | 2023-2024 | Apretude |
| Astellas Pharma US INC | $95.55 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $92.51 | 2022-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $74.76 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Ardelyx, INC. | $57.77 | 2024-2025 | Ibsrela |
| Allergan, INC. | $49.31 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $47.87 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $47.54 | 2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.43 | 2024-2025 | Xifaxan |
| Sanofi Pasteur INC. | $39.58 | 2019-2021 | |
| Esperion Therapeutics, INC. | $33.89 | 2020-2024 | Nexletol |
| Phadia US INC. | $32.57 | 2025 | Immunocap |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.00 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $26.69 | 2022 | |
| Sumitomo Pharma America, INC. | $22.65 | 2024 | Gemtesa |
| Inspire Medical Systems, INC. | $20.78 | 2024 | Inspire |
| Intuity Medical INC | $20.25 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Genentech USA, INC. | $19.08 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.90 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.35 | 2023 | Seglentis |
| Eisai INC. | $13.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Candanosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.